DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
Drug-Coated Stent Versus Drug-Eluting Stent for One-month Dual-antiplatelet Therapy in Patients With Acute Coronary Syndrome: ONE-PASS Trial
Yonsei University
3,520 participants
Aug 10, 2022
INTERVENTIONAL
Conditions
Summary
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.
Eligibility
Inclusion Criteria3
- Age ≥19 years
- All subjects who are acceptable candidates for treatment with a drug-coated stent or drug-eluting stent because of acute coronary syndrome
- Provision of informed consent
Exclusion Criteria3
- Current or potential pregnancy
- Need of oral anticoagulation therapy
- Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05305482